{"id":59792,"date":"2024-11-21T06:00:10","date_gmt":"2024-11-21T11:00:10","guid":{"rendered":"https:\/\/www.ino.com\/blog\/?p=59792"},"modified":"2024-11-21T22:22:28","modified_gmt":"2024-11-22T03:22:28","slug":"biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock","status":"publish","type":"post","link":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/","title":{"rendered":"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock?"},"content":{"rendered":"

The biotech landscape is being reshaped by advances in mRNA technology, particularly in cancer research.<\/span> Moderna, Inc. (MRNA)<\/span><\/a>, a pioneer of mRNA-based therapies, has shifted from its pandemic-era focus on COVID-19 vaccines to explore applications in oncology. Its approach to leveraging mRNA\u2019s ability to program cells to fight cancer marks a revolutionary step in personalized medicine.<\/span><\/p>\n

At the forefront of this innovation is Moderna's collaboration with<\/span> Merck & Co., Inc. (MRK)<\/span><\/a> to develop Individualized Neoantigen Therapy (INT). This therapy customizes cancer vaccines based on a patient\u2019s specific tumor mutations, aiming to train the immune system to target malignancies effectively. With<\/span> Phase 3 trials underway<\/span><\/a> for mRNA-4157 in combination with Keytruda, Moderna\u2019s oncology ambitions are gaining momentum\u200b.<\/span><\/p>\n

Moderna\u2019s Expansion Beyond COVID-19<\/b><\/p>\n

While Moderna achieved global recognition for its COVID-19 vaccine, it has been diversifying aggressively. It has 36 development candidates across 45 development programs, of which 42 are currently in clinical studies.<\/span><\/p>\n

Beyond oncology, Moderna is focusing on vaccines for infectious diseases like RSV and influenza, many of which are in late-stage trials. The company aims for<\/span> 10 product approvals by 2027<\/span><\/a>, signaling its broader vision of dominating multiple therapeutic domains.<\/span><\/p>\n

Financial Stability and Growth Potential\u00a0<\/b><\/p>\n

Despite diversification, Moderna remains financially reliant on COVID-19 product sales, which contributed $1.8 billion of its $1.9 billion Q3 2024 revenue. However, the company's $9.2 billion cash reserve offers a solid cushion to fund its pipeline.\u00a0<\/span><\/p>\n

Revenue from oncology programs has not yet been realized, but analysts project significant long-term growth. The global oncology drug market is expected to grow at a compound annual growth rate (CAGR) of 12.6%, potentially hitting<\/span> $532.91 billion by 2031<\/span><\/a>. Moderna's advancements in oncology position it to capture a slice of this market, though its current reliance on respiratory vaccines highlights a transitional period.\u00a0<\/span><\/p>\n

Operational efficiency has improved significantly. Year-over-year, selling, general, and administrative expenses dropped 36% in Q3, indicating better cost management as the company scales its operations.<\/span><\/p>\n

Key Risks and Challenges\u00a0<\/b><\/p>\n

Biotechnology is not without its hurdles. For Moderna, competition in oncology looms large. Rivals like<\/span> BioNTech SE (BNTX)<\/span><\/a> and<\/span> Gilead Sciences, Inc. (GILD)<\/span><\/a> are also innovating in the mRNA and immunotherapy spaces, vying for a similar market.\u00a0<\/span><\/p>\n

Regulatory scrutiny presents another challenge. The INTs and other therapies must clear rigorous approval processes before commercialization. Delays or failures could impact Moderna\u2019s ability to generate non-COVID revenue streams promptly. Moreover, reliance on partnerships, such as its collaboration with Merck, means the company shares both financial risk and rewards.\u00a0<\/span><\/p>\n

Lastly, Moderna\u2019s revenue concentration on COVID-19 products, though gradually diversifying, exposes it to fluctuations in vaccine demand. The decline in pandemic-related sales\u2014evident in the reduction of deferred revenues from<\/span> $613 million in 2023 to $443 million in 2024<\/span><\/a>\u2014highlights this vulnerability.<\/span><\/p>\n

Investor Takeaway<\/b><\/p>\n

Moderna represents a compelling investment for growth-oriented investors with an appetite for risk. The company's deep pipeline, robust financial health, and focus on mRNA technology across oncology and infectious diseases position it as a frontrunner in the biotech sector. However, potential investors should be mindful of the risks tied to regulatory approvals and competitive pressures.<\/span><\/p>\n

For those considering long-term exposure to the biotech space, Moderna\u2019s strategic pivot toward cancer research, coupled with its financial discipline, makes it an intriguing candidate. As always, diversification within a portfolio can help mitigate risks associated with such high-growth stocks.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

The biotech landscape is being reshaped by advances in mRNA technology, particularly in cancer research. Moderna, Inc. (MRNA), a pioneer of mRNA-based therapies, has shifted from its pandemic-era focus on COVID-19 vaccines to explore applications in oncology. Its approach to leveraging mRNA\u2019s ability to program cells to fight cancer marks a revolutionary step in personalized […]<\/p>\n","protected":false},"author":41,"featured_media":58704,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[35032,35028,35033,35031,35029,35030,32518,35036,32517,35035,35034],"class_list":["post-59792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","tag-532-91-billion-by-2031","tag-613-million-in-2023-to-443-million-in-2024","tag-10-product-approvals-by-2027","tag-biontech-se-bntx","tag-gilead-sciences","tag-inc-gild","tag-inc-mrk","tag-inc-mrna","tag-merck-co","tag-moderna","tag-phase-3-trials-underway"],"yoast_head":"\nBiotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock? - INO.com Trader's Blog<\/title>\n<meta name=\"description\" content=\"Moderna's groundbreaking strides in mRNA cancer therapies signal long-term growth potential. Discover its oncology pipeline, financial health, and investment risks in this deep dive.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock? - INO.com Trader's Blog\" \/>\n<meta property=\"og:description\" content=\"Moderna's groundbreaking strides in mRNA cancer therapies signal long-term growth potential. Discover its oncology pipeline, financial health, and investment risks in this deep dive.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\" \/>\n<meta property=\"og:site_name\" content=\"INO.com Trader's Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/inocom\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-21T11:00:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-22T03:22:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"The INO.com Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"The INO.com Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\"},\"author\":{\"name\":\"The INO.com Team\",\"@id\":\"https:\/\/www.ino.com\/blog\/#\/schema\/person\/d86a8cce826b7bd105200d88bb28a280\"},\"headline\":\"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock?\",\"datePublished\":\"2024-11-21T11:00:10+00:00\",\"dateModified\":\"2024-11-22T03:22:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\"},\"wordCount\":549,\"publisher\":{\"@id\":\"https:\/\/www.ino.com\/blog\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png\",\"keywords\":[\"$532.91 billion by 2031\",\"$613 million in 2023 to $443 million in 2024\",\"10 product approvals by 2027\",\"BioNTech SE (BNTX)\",\"Gilead Sciences\",\"Inc. (GILD)\",\"Inc. (MRK)\",\"Inc. (MRNA)\",\"Merck & Co.\",\"Moderna\",\"Phase 3 trials underway\"],\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\",\"url\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\",\"name\":\"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock? - INO.com Trader's Blog\",\"isPartOf\":{\"@id\":\"https:\/\/www.ino.com\/blog\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png\",\"datePublished\":\"2024-11-21T11:00:10+00:00\",\"dateModified\":\"2024-11-22T03:22:28+00:00\",\"description\":\"Moderna's groundbreaking strides in mRNA cancer therapies signal long-term growth potential. Discover its oncology pipeline, financial health, and investment risks in this deep dive.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage\",\"url\":\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png\",\"contentUrl\":\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png\",\"width\":1200,\"height\":630},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ino.com\/blog\/#website\",\"url\":\"https:\/\/www.ino.com\/blog\/\",\"name\":\"INO.com Trader's Blog\",\"description\":\"Expert Charts, Trading Tips and Technical Analysis from INO.com\",\"publisher\":{\"@id\":\"https:\/\/www.ino.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ino.com\/blog\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ino.com\/blog\/#organization\",\"name\":\"INO.com Trader's Blog\",\"url\":\"https:\/\/www.ino.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ino.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2018\/12\/inologo-400.jpg\",\"contentUrl\":\"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2018\/12\/inologo-400.jpg\",\"width\":400,\"height\":472,\"caption\":\"INO.com Trader's Blog\"},\"image\":{\"@id\":\"https:\/\/www.ino.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/inocom\/\",\"https:\/\/www.linkedin.com\/company-beta\/1056449\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ino.com\/blog\/#\/schema\/person\/d86a8cce826b7bd105200d88bb28a280\",\"name\":\"The INO.com Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ino.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/cb06ce065c1db526fc31f4d08d898a30?s=96&d=identicon&r=pg\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/cb06ce065c1db526fc31f4d08d898a30?s=96&d=identicon&r=pg\",\"caption\":\"The INO.com Team\"},\"url\":\"https:\/\/www.ino.com\/blog\/author\/the-ino-com-team\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock? - INO.com Trader's Blog","description":"Moderna's groundbreaking strides in mRNA cancer therapies signal long-term growth potential. Discover its oncology pipeline, financial health, and investment risks in this deep dive.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/","og_locale":"en_US","og_type":"article","og_title":"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock? - INO.com Trader's Blog","og_description":"Moderna's groundbreaking strides in mRNA cancer therapies signal long-term growth potential. Discover its oncology pipeline, financial health, and investment risks in this deep dive.","og_url":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/","og_site_name":"INO.com Trader's Blog","article_publisher":"https:\/\/www.facebook.com\/inocom\/","article_published_time":"2024-11-21T11:00:10+00:00","article_modified_time":"2024-11-22T03:22:28+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png","type":"image\/png"}],"author":"The INO.com Team","twitter_card":"summary_large_image","twitter_misc":{"Written by":"The INO.com Team","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#article","isPartOf":{"@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/"},"author":{"name":"The INO.com Team","@id":"https:\/\/www.ino.com\/blog\/#\/schema\/person\/d86a8cce826b7bd105200d88bb28a280"},"headline":"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock?","datePublished":"2024-11-21T11:00:10+00:00","dateModified":"2024-11-22T03:22:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/"},"wordCount":549,"publisher":{"@id":"https:\/\/www.ino.com\/blog\/#organization"},"image":{"@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png","keywords":["$532.91 billion by 2031","$613 million in 2023 to $443 million in 2024","10 product approvals by 2027","BioNTech SE (BNTX)","Gilead Sciences","Inc. (GILD)","Inc. (MRK)","Inc. (MRNA)","Merck & Co.","Moderna","Phase 3 trials underway"],"articleSection":["General"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/","url":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/","name":"Biotech Advances in Cancer Research: Is Moderna (MRNA) a Long-Term Growth Stock? - INO.com Trader's Blog","isPartOf":{"@id":"https:\/\/www.ino.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage"},"image":{"@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png","datePublished":"2024-11-21T11:00:10+00:00","dateModified":"2024-11-22T03:22:28+00:00","description":"Moderna's groundbreaking strides in mRNA cancer therapies signal long-term growth potential. Discover its oncology pipeline, financial health, and investment risks in this deep dive.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ino.com\/blog\/2024\/11\/biotech-advances-in-cancer-research-is-moderna-mrna-a-long-term-growth-stock\/#primaryimage","url":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png","contentUrl":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2023\/06\/Untitled-design-38.png","width":1200,"height":630},{"@type":"WebSite","@id":"https:\/\/www.ino.com\/blog\/#website","url":"https:\/\/www.ino.com\/blog\/","name":"INO.com Trader's Blog","description":"Expert Charts, Trading Tips and Technical Analysis from INO.com","publisher":{"@id":"https:\/\/www.ino.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ino.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ino.com\/blog\/#organization","name":"INO.com Trader's Blog","url":"https:\/\/www.ino.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ino.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2018\/12\/inologo-400.jpg","contentUrl":"https:\/\/www.ino.com\/blog\/wp-content\/uploads\/2018\/12\/inologo-400.jpg","width":400,"height":472,"caption":"INO.com Trader's Blog"},"image":{"@id":"https:\/\/www.ino.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/inocom\/","https:\/\/www.linkedin.com\/company-beta\/1056449\/"]},{"@type":"Person","@id":"https:\/\/www.ino.com\/blog\/#\/schema\/person\/d86a8cce826b7bd105200d88bb28a280","name":"The INO.com Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ino.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/cb06ce065c1db526fc31f4d08d898a30?s=96&d=identicon&r=pg","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cb06ce065c1db526fc31f4d08d898a30?s=96&d=identicon&r=pg","caption":"The INO.com Team"},"url":"https:\/\/www.ino.com\/blog\/author\/the-ino-com-team\/"}]}},"_links":{"self":[{"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/posts\/59792"}],"collection":[{"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/users\/41"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/comments?post=59792"}],"version-history":[{"count":0,"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/posts\/59792\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/media\/58704"}],"wp:attachment":[{"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/media?parent=59792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/categories?post=59792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ino.com\/blog\/wp-json\/wp\/v2\/tags?post=59792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}